Abstract
The study of photodynamic therapy (PDT) has been given increasing attention, especially the use of hematoporphyrin derivative (HpD). Recently, Mono-L-serinyl chlorin e6 (NIPPON PETROCHEMICAL CO., LTD.) has been developed as a new photosensitizer for PDT. This material is considered to be useful for PDT due to its greater absorption band in the wavelengths longer than these of HpD. We studied the distribution Mono-L-serinyl chlorin e6 (20mg/kg weight) was administered intravenously via the tail of tumor-bearing mice. The relative intensity of fruolescence from a tumor and other tissues were accumulated most at 3hrs after in jection. And at 24hrs after injection, the intensity from other tissues decreased by about 20% of the intensity from the tumor at 3hrs after injection. Additionaly, mice were illuminated 24hrs after injection, the mice received Mon-L-serinyl chlorin e6 showed hardly skin damage versus mice received PHOTOFRIN II of skin damage.
These results suggest that Mono-L-serinyl chlorin e6 may be used in photodynamic therapy at an early stage.
